igf-1

IGF-I 30-41 acetate(82177-09-1 free base) (Insulin-like Growth Factor I (30-41) acetate) is amino acids 30 to 41 fragment of Insulin-like Growth Factor I (IGF-I).

IGF-I (30-41) (TFA) is amino acids 30 to 41 fragment of Insulin-like Growth Factor I (IGF-I).

Preptin, an osteogenic peptide derived from pancreatic beta-cells, spans amino acids Asp 69 to Leu 102 within pro-IGF-II [1].

Insulin-like Growth Factor I (24-41) TFA, a fragment comprising amino acids 24 to 41 of the full IGF-I TFA molecule, is a variant of IGF-I TFA, which itself is a 70 amino acid polypeptide hormone. This hormone serves as a trophic factor beneficial for both neurons and glial cells, playing a significant role in mediating the effects of growth hormone (GH) on systemic growth. Additionally, IGF-I TFA exhibits anabolic, antioxidant, anti-inflammatory, and cytoprotective properties. The specific fragment IGF-I (24-41) TFA is involved in regulating somatic growth as well as behavioral development [1] [2] [3].

Angiopeptin TFA, a cyclic octapeptide analogue of somatostatin, acts as a partial agonist at sst 2/sst 5 receptors, exhibiting IC50 values of 0.26 nM and 6.92 nM, respectively. This compound effectively inhibits the release of growth hormone and the production of insulin-like growth factor-1 (IGF-1). Additionally, it either inhibits adenylate cyclase activity or promotes extracellular acidification. Notably, Angiopeptin TFA shows promise for use in coronary atherosclerosis research [1] [2].

Trofinetide, derived from the neuroprotective tripeptide Gly-Pro-Glu (an N-terminal sequence of insulin-like growth factor-1, IGF-1), shows promise in various neuroprotective models. At a concentration of 10 nM, it mitigates cell death in primary rat embryonic striatal neurons caused by okadaic acid. Additionally, Trofinetide reduces the expression of pro-inflammatory markers (IL-1β, TNF-α, IL-6, and E-selectin) in a rat model simulating neuroinflammation from penetrating ballistic-like brain injuries. In cases of brain injury induced by middle cerebral artery occlusion (MCAO), administration of Trofinetide at 30 and 60 mg/kg reduces the area of cortical and striatal infarct. Furthermore, a daily dose of 100 mg/kg reverses social recognition and contextual fear conditioning deficits, diminishes the number of dendritic spines, and decreases testicular weight gain in an fmr1-/- knockout mouse model of fragile X syndrome. Trofinetide formulations have been employed in treating Rett syndrome, highlighting its versatility across various neurological conditions.

Mecasermin (Human IGF-I; FK 780), a recombinant form of human insulin-like growth factor I (IGF-I), holds promise for investigating growth failure attributed to growth hormone (GH) insensitivity, which may be due to defects in GH receptors or the presence of GH-inhibiting antibodies [1].

IGF-I (30-41) (TFA) is a fragment consisting of amino acids 30 to 41 from Insulin-like Growth Factor I (IGF-I), a compound responsible in part for systemic GH (Growth Hormone) activities. It exhibits an array of properties including anabolic, antioxidant, anti-inflammatory, and cytoprotective actions [1].